Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00224107 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.

NCT NCT00224107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00224107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
Watson Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
August 31, 2006
Enrollment
461 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)